Atara Biotherapeutics, Inc.
ATRA evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $94.2M
- Lead Asset:
- tab-cel (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ATRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATRA
Atara Biotherapeutics is a biotechnology company focused on developing allogeneic T-cell immunotherapies, with its lead candidate tab-cel (tabelecleucel) for EBV+ PTLD facing regulatory and financial challenges.
Key risk: Cash runway insufficient
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$94.2M
Cash Runway
—
Lead Asset
tab-cel (Phase 3)
Next Catalyst
—
Tracking 1 pipeline candidate · 2 clinical trials for Atara Biotherapeutics, Inc..
Atara Biotherapeutics is a biotechnology company focused on developing allogeneic T-cell immunotherapies, with its lead candidate tab-cel (tabelecleucel) for EBV+ PTLD facing regulatory and financial challenges.
- Atara's lead candidate tab-cel (tabelecleucel) is an allogeneic EBV-specific T-cell immunotherapy in Phase 3 for EBV+ PTLD, with Breakthrough Therapy and Orphan Drug designations [pipeline].
- The FDA issued a Complete Response Letter for the tab-cel BLA, and clinical holds were placed on active INDs due to observations from a pre-license inspection of a third-party manufacturing facility [sec · filed 2025-04-28].
- As of June 30, 2026, Atara's existing cash, cash equivalents and short-term investments will not be sufficient to fund planned operations, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-12].
- Atara has one approved product, Ebvallo, in the European Economic Area, UK, and Switzerland, but relies on partner Pierre Fabre for commercialization and manufacturing of tab-cel [sec_mda · as of 2026-03-16].
- A Phase 3 trial (ALLELE) for tab-cel showed objective responses in 50% of HSCT and 52% of SOT participants after failure of rituximab-based therapy [catalyst].
What works
- Tab-cel has received Breakthrough Therapy and Orphan Drug designations from the FDA, indicating regulatory recognition of its potential [pipeline].
- Phase 3 trial data showed objective responses in 50% of HSCT and 52% of SOT recipients, demonstrating clinical activity in a niche indication [catalyst].
- Atara has an approved product (Ebvallo) in the EEA, UK, and Switzerland, providing some commercial validation [sec_mda · as of 2026-03-16].
- The partnership with Pierre Fabre provides a pathway for global commercialization and manufacturing of tab-cel, with milestone and royalty payments [pipeline].
What to weigh
- Atara's existing cash as of June 30, 2026 is insufficient to fund planned operations, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-12].
- The FDA issued a Complete Response Letter for the tab-cel BLA and placed clinical holds on active INDs due to third-party manufacturing facility observations [sec · filed 2025-04-28].
- Atara anticipates continued losses and expects accumulated losses to increase as it seeks regulatory approvals, with no committed external funding beyond potential milestone payments [sec_mda · as of 2025-11-12].
- The company does not retain meaningful milestone or royalty payments from Pierre Fabre for the Initial Territory until a royalty cap under the HCRx Agreement is met [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
FDA issued Complete Response Letter for tab-cel BLA and clinical holds due to manufacturing facility observations
“we were disappointed by the Complete Response Letter to the tab-cel BLA from the FDA and clinical holds on our active INDs, which were solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility”
SEC filings · April 28, 2025
Cash position insufficient to fund operations as of June 30, 2026
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations”
SEC MD&A · August 12, 2026
Phase 3 ALLELE trial objective response rates
“Seven (50%, 95% CI 23-77) of 14 participants in the HSCT group and 15 (52%, 33-71) of 29 participants in the SOT group had an objective response”
Catalysts · March 31, 2024
Atara has one approved product, Ebvallo, in EEA, UK, and Switzerland
“We have one approved product, Ebvallo, which is currently approved in the European Economic Area (EEA), the UK and Switzerland.”
SEC MD&A · March 16, 2026
Catalyst timeline
- 2017-12-29 · Phase 3 study start for tabelecleucel in EBV+ PTLD — Multicenter, open-label Phase 3 study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with EBV-associated PTLD after failure of rituximab or rituximab and chemotherapy.
- 2024-03-31 · Trial readout for ALLELE Phase 3 — Reported objective response rates of 50% in HSCT and 52% in SOT groups; results published in a multicentre, open-label trial.
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash as of June 30, 2026 not enough to fund planned operations; substantial doubt about going concern [sec_mda · as of 2026-08-12].
- Regulatory setbacks for tab-cel — FDA Complete Response Letter and clinical holds due to third-party manufacturing issues [sec · filed 2025-04-28].
- Dependence on partner milestones — No committed external funding; milestone/royalty payments from Pierre Fabre subject to HCRx cap [sec_mda · as of 2026-08-12].
- Continued operating losses — Accumulated losses expected to increase; no near-term revenue to offset expenses [sec_mda · as of 2025-11-12].
What to watch
- Ability to secure additional funding to extend cash runway beyond mid-2026 [sec_mda · as of 2026-08-12].
- Resolution of FDA Complete Response Letter and clinical holds for tab-cel, including third-party manufacturing remediation [sec · filed 2025-04-28].
- Progress of tab-cel regulatory approval in Europe via Pierre Fabre partnership [pipeline].
- Any updates on the Phase 3 ALLELE trial or expansion of CAR-T programs like ATA3219 [sec · filed 2025-04-28].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run Atara Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Atara Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
2 buys · 3 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 5.3%
- Days to cover
- 4.7
- Shares short
- 306,093
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Atara Biotherapeutics, Inc.?
Atara Biotherapeutics is a biotechnology company focused on developing allogeneic T-cell immunotherapies, with its lead candidate tab-cel (tabelecleucel) for EBV+ PTLD facing regulatory and financial challenges.
What is Atara Biotherapeutics, Inc.'s lead drug candidate?
Atara Biotherapeutics, Inc.'s most advanced tracked candidate is tab-cel (Phase 3) for EBV+ PTLD.
Who is the CEO of Atara Biotherapeutics, Inc.?
Dr. Anhco Nguyen Ph.D. is the chief executive officer of Atara Biotherapeutics, Inc. (ATRA).
Where is Atara Biotherapeutics, Inc. headquartered?
Atara Biotherapeutics, Inc. (ATRA) is headquartered in Thousand Oaks, CA, United States.
What therapeutic areas does Atara Biotherapeutics, Inc. focus on?
Atara Biotherapeutics, Inc. develops therapies across Oncology, Gene Therapy.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.